Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Sharecare 'offers excelling buying opportunity', says BTIG » 09:31
11/24/21
11/24
09:31
11/24/21
09:31
SHCR

Sharecare

$5.92 /

-0.3 (-4.82%)

BTIG analyst David Larsen…

BTIG analyst David Larsen keeps his Buy rating and $15 price target on Sharecare after his meeting with its management and investors supported his view that the company offers a "high-quality solution with very loyal clients" and that it will continue to add lives to the Enterprise platform. The stock has been under enormous pressure along with many other SPAC and health-tech stocks, but as shares unlock and as liquidity improves, Sharecare offers an "excellent buying opportunity", Larsen tells investors in a research note.

ShowHide Related Items >><<
SHCR Sharecare
$5.92 /

-0.3 (-4.82%)

SHCR Sharecare
$5.92 /

-0.3 (-4.82%)

11/11/21 Canaccord
Sharecare price target raised to $12 at Canaccord after Q3 beat
11/10/21 BTIG
Sharecare deliveries 'solid' beat in second quarter as public company, says BTIG
10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
SHCR Sharecare
$5.92 /

-0.3 (-4.82%)

SHCR Sharecare
$5.92 /

-0.3 (-4.82%)

Conference/Events
Sharecare management to meet virtually with BTIG » 04:55
11/16/21
11/16
04:55
11/16/21
04:55
SHCR

Sharecare

$7.44 /

-0.33 (-4.25%)

Virtual Meeting to be…

Virtual Meeting to be held on November 16 hosted by BTIG.

ShowHide Related Items >><<
SHCR Sharecare
$7.44 /

-0.33 (-4.25%)

SHCR Sharecare
$7.44 /

-0.33 (-4.25%)

11/11/21 Canaccord
Sharecare price target raised to $12 at Canaccord after Q3 beat
11/10/21 BTIG
Sharecare deliveries 'solid' beat in second quarter as public company, says BTIG
10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
SHCR Sharecare
$7.44 /

-0.33 (-4.25%)

SHCR Sharecare
$7.44 /

-0.33 (-4.25%)

Recommendations
Sharecare price target raised to $12 at Canaccord after Q3 beat » 08:05
11/11/21
11/11
08:05
11/11/21
08:05
SHCR

Sharecare

$7.92 /

+0.7 (+9.70%)

Canaccord analyst Richard…

Canaccord analyst Richard Close raised the firm's price target on Sharecare to $12 from $11 and keeps a Buy rating on the shares after the company beat his revenue and adjusted EBITDA estimates and Q3 guidance in what Close called "essentially its first full quarter as a public company following the July SPAC merger." Close adds that "not all SPACs are equal" as Sharecare has "a real business that is diversified and most importantly profitable." With revenue guidance maintained and the lower end of adjusted EBITDA guidance raised, Sharecare looks positioned to deliver on its targets for 2021, the analyst added.

ShowHide Related Items >><<
SHCR Sharecare
$7.92 /

+0.7 (+9.70%)

SHCR Sharecare
$7.92 /

+0.7 (+9.70%)

11/10/21 BTIG
Sharecare deliveries 'solid' beat in second quarter as public company, says BTIG
10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
08/11/21 BTIG
Sharecare's Q2 results 'excellent,' 'impressive' level of visibility, says BTIG
SHCR Sharecare
$7.92 /

+0.7 (+9.70%)

SHCR Sharecare
$7.92 /

+0.7 (+9.70%)

Recommendations
Sharecare deliveries 'solid' beat in second quarter as public company, says BTIG » 10:58
11/10/21
11/10
10:58
11/10/21
10:58
SHCR

Sharecare

$7.43 /

+0.21 (+2.91%)

BTIG analyst David Larsen…

BTIG analyst David Larsen tells investors in a research note that Sharecare delivered a "solid" revenue and EBITDA beat, and this is important as it is only the second quarter that the company has reported as a public company. Larsen, who made no change to his Buy rating or $15 price target, feels management is under-promising and over-delivering, adding that Sharecare is one of the highest quality digital health investments available to the market.

ShowHide Related Items >><<
SHCR Sharecare
$7.43 /

+0.21 (+2.91%)

SHCR Sharecare
$7.43 /

+0.21 (+2.91%)

10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
08/11/21 BTIG
Sharecare's Q2 results 'excellent,' 'impressive' level of visibility, says BTIG
08/04/21 Canaccord
Sharecare initiated with a Buy at Canaccord
SHCR Sharecare
$7.43 /

+0.21 (+2.91%)

SHCR Sharecare
$7.43 /

+0.21 (+2.91%)

Earnings
Sharecare still sees FY21 revenue $414M-$415M, consensus $413.13M » 07:17
11/10/21
11/10
07:17
11/10/21
07:17
SHCR

Sharecare

$7.22 /

+0.11 (+1.55%)

Raises adjusted EBITDA…

Raises adjusted EBITDA view to $29M-$30M, an increase in the midpoint of guidance range.

ShowHide Related Items >><<
SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
08/11/21 BTIG
Sharecare's Q2 results 'excellent,' 'impressive' level of visibility, says BTIG
08/04/21 Canaccord
Sharecare initiated with a Buy at Canaccord
SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

Earnings
Sharecare sees Q4 $120.3M-$121.3M, consensus $121.53M » 07:16
11/10/21
11/10
07:16
11/10/21
07:16
SHCR

Sharecare

$7.22 /

+0.11 (+1.55%)

Sees Q4 adjusted EBITDA…

Sees Q4 adjusted EBITDA in the range of $8M-$9M.

ShowHide Related Items >><<
SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
08/11/21 BTIG
Sharecare's Q2 results 'excellent,' 'impressive' level of visibility, says BTIG
08/04/21 Canaccord
Sharecare initiated with a Buy at Canaccord
SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

Earnings
Sharecare reports Q3 adjusted EPS 0c, consensus (3c) » 07:15
11/10/21
11/10
07:15
11/10/21
07:15
SHCR

Sharecare

$7.22 /

+0.11 (+1.55%)

Reports Q3 revenue…

Reports Q3 revenue $105.6M, consensus $103.52M. "Our team delivered strong revenue and adjusted EBITDA ahead of guidance while increasing our investment in technology and sales to drive consistent double-digit growth going forward," said CEO Jeff Arnold. "All channels demonstrated strong underlying trends with Enterprise moving closer to our goal of nearly 10 million lives on the platform by year-end, Provider delivering strong record retrieval volumes, and Consumer adding a significant number of new brands to its roster at higher average revenue per program. The strength of our performance across all channels in the quarter and year-to-date supports the increase in the midpoint of our adjusted EBITDA guidance for the year as well as sets a strong foundation to deliver on our fiscal 2022 outlook."

ShowHide Related Items >><<
SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
08/11/21 BTIG
Sharecare's Q2 results 'excellent,' 'impressive' level of visibility, says BTIG
08/04/21 Canaccord
Sharecare initiated with a Buy at Canaccord
SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

Conference/Events
CNS Summit to hold a summit » 04:55
11/10/21
11/10
04:55
11/10/21
04:55
OTSKY

Otsuka

$19.65 /

-0.21 (-1.06%)

, SYNH

Syneos Health

$101.27 /

-0.4 (-0.39%)

, CERE

Cerevel Therapeutics

$43.53 /

-0.975 (-2.19%)

, TAK

Takeda Pharmaceutical

$14.46 /

+0.065 (+0.45%)

, REGN

Regeneron

$615.79 /

-6.7 (-1.08%)

, PFE

Pfizer

$47.30 /

-1.03 (-2.13%)

, AVNR

Avanir

$16.96 /

+ (+0.00%)

, KRTX

Karuna Therapeutics

$151.44 /

-0.56 (-0.37%)

, ABBV

AbbVie

$115.62 /

-0.385 (-0.33%)

, CYCN

Cyclerion Therapeutics

$2.77 /

-0.09 (-3.15%)

, YMTX

Yumanity Therapeutics

$8.43 /

-0.39 (-4.42%)

, ALTO

Alto Ingredients

$5.73 /

-0.24 (-4.02%)

, APTX

Aptinyx

$2.30 /

-0.03 (-1.29%)

, MRK

Merck

$82.75 /

+0.065 (+0.08%)

, BMY

Bristol-Myers

$59.46 /

+0.065 (+0.11%)

, SHCR

Sharecare

$7.22 /

+0.11 (+1.55%)

12th Annual CNS Summit to…

12th Annual CNS Summit to be held in Boston on November 7-10.

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$8.43 /

-0.39 (-4.42%)

TAK Takeda Pharmaceutical
$14.46 /

+0.065 (+0.45%)

SYNH Syneos Health
$101.27 /

-0.4 (-0.39%)

SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

REGN Regeneron
$615.79 /

-6.7 (-1.08%)

PFE Pfizer
$47.30 /

-1.03 (-2.13%)

OTSKY Otsuka
$19.65 /

-0.21 (-1.06%)

MRK Merck
$82.75 /

+0.065 (+0.08%)

KRTX Karuna Therapeutics
$151.44 /

-0.56 (-0.37%)

CYCN Cyclerion Therapeutics
$2.77 /

-0.09 (-3.15%)

CERE Cerevel Therapeutics
$43.53 /

-0.975 (-2.19%)

BMY Bristol-Myers
$59.46 /

+0.065 (+0.11%)

APTX Aptinyx
$2.30 /

-0.03 (-1.29%)

ALTO Alto Ingredients
$5.73 /

-0.24 (-4.02%)

ABBV AbbVie
$115.62 /

-0.385 (-0.33%)

OTSKY Otsuka
$19.65 /

-0.21 (-1.06%)

07/14/21 Goldman Sachs
Otsuka downgraded to Sell from Neutral at Goldman Sachs
06/17/21 Daiwa
Otsuka upgraded to Outperform from Neutral at Daiwa
03/15/21 Daiwa
Otsuka downgraded to Neutral from Outperform at Daiwa
SYNH Syneos Health
$101.27 /

-0.4 (-0.39%)

11/04/21 Baird
Syneos Health price target raised to $122 from $115 at Baird
11/04/21 Barclays
Syneos Health upgraded to Overweight from Equal Weight at Barclays
08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
CERE Cerevel Therapeutics
$43.53 /

-0.975 (-2.19%)

10/08/21 Jefferies
Cerevel Therapeutics price target raised to $37 from $30 at Jefferies
09/22/21 Stifel
CFO transition impact on Cerevel Therapeutics 'likely minimal,' says Stifel
07/13/21 Stifel
Cerevel Therapeutics price target raised to $33 from $21 at Stifel
06/30/21 Citi
Karuna Therapeutics selloff brings buying opportunity, says Citi
TAK Takeda Pharmaceutical
$14.46 /

+0.065 (+0.45%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
REGN Regeneron
$615.79 /

-6.7 (-1.08%)

11/09/21 Benchmark
Benchmark sees signs Regeneron may be planning large acquisition
11/05/21
Fly Intel: Top five analyst downgrades
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/05/21 H.C. Wainwright
Regeneron price target raised to $844 from $842 at H.C. Wainwright
PFE Pfizer
$47.30 /

-1.03 (-2.13%)

11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
AVNR Avanir
$16.96 /

+ (+0.00%)

KRTX Karuna Therapeutics
$151.44 /

-0.56 (-0.37%)

11/08/21 Oppenheimer
Karuna Therapeutics price target raised to $175 from $148 at Oppenheimer
11/05/21 Mizuho
Karuna Therapeutics price target raised to $182 from $150 at Mizuho
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
09/30/21 JPMorgan
Karuna Therapeutics initiated with an Overweight at JPMorgan
ABBV AbbVie
$115.62 /

-0.385 (-0.33%)

11/01/21 Morgan Stanley
AbbVie price target raised to $124 from $116 at Morgan Stanley
10/29/21 Piper Sandler
AbbVie price target raised to $129 from $124 at Piper Sandler
10/19/21 Morgan Stanley
Regenxbio assumed with an Overweight at Morgan Stanley
10/05/21 Piper Sandler
Biohaven Pharmaceutical price target raised to $156 from $140 at Piper Sandler
CYCN Cyclerion Therapeutics
$2.77 /

-0.09 (-3.15%)

10/20/21 Truist
Cyclerion Therapeutics initiated with a Buy at Truist
10/20/21 Truist
Cyclerion Therapeutics initiated with a Buy at Truist
09/24/21 Cantor Fitzgerald
Cyclerion Therapeutics initiated with an Overweight at Cantor Fitzgerald
YMTX Yumanity Therapeutics
$8.43 /

-0.39 (-4.42%)

09/08/21 Piper Sandler
Yumanity should be bought ahead of Parkinson's data, says Piper Sandler
06/04/21 H.C. Wainwright
Yumanity Therapeutics initiated with a Buy at H.C. Wainwright
04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
ALTO Alto Ingredients
$5.73 /

-0.24 (-4.02%)

APTX Aptinyx
$2.30 /

-0.03 (-1.29%)

01/29/21 JPMorgan
Aptinyx downgraded to Underweight from Neutral at JPMorgan
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
11/19/20 H.C. Wainwright
Aptinyx price target raised to $8 from $7 at H.C. Wainwright
11/12/20 Piper Sandler
Aptinyx pipeline catalysts on track, says Piper Sandler
MRK Merck
$82.75 /

+0.065 (+0.08%)

11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
BMY Bristol-Myers
$59.46 /

+0.065 (+0.11%)

11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
11/01/21 Argus
Bristol-Myers cut to Hold at Argus on generic competition threat to Revlimid
11/01/21 Argus
Bristol-Myers downgraded to Hold from Buy at Argus
10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
08/11/21 BTIG
Sharecare's Q2 results 'excellent,' 'impressive' level of visibility, says BTIG
08/04/21 Canaccord
Sharecare initiated with a Buy at Canaccord
YMTX Yumanity Therapeutics
$8.43 /

-0.39 (-4.42%)

SYNH Syneos Health
$101.27 /

-0.4 (-0.39%)

SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

REGN Regeneron
$615.79 /

-6.7 (-1.08%)

PFE Pfizer
$47.30 /

-1.03 (-2.13%)

MRK Merck
$82.75 /

+0.065 (+0.08%)

KRTX Karuna Therapeutics
$151.44 /

-0.56 (-0.37%)

CERE Cerevel Therapeutics
$43.53 /

-0.975 (-2.19%)

BMY Bristol-Myers
$59.46 /

+0.065 (+0.11%)

APTX Aptinyx
$2.30 /

-0.03 (-1.29%)

ALTO Alto Ingredients
$5.73 /

-0.24 (-4.02%)

ABBV AbbVie
$115.62 /

-0.385 (-0.33%)

  • 10
    Nov
  • 02
    Jul
  • 03
    Jun
  • 04
    May
  • 01
    Mar
  • 02
    Mar
  • 02
    Dec
TAK Takeda Pharmaceutical
$14.46 /

+0.065 (+0.45%)

REGN Regeneron
$615.79 /

-6.7 (-1.08%)

PFE Pfizer
$47.30 /

-1.03 (-2.13%)

OTSKY Otsuka
$19.65 /

-0.21 (-1.06%)

MRK Merck
$82.75 /

+0.065 (+0.08%)

BMY Bristol-Myers
$59.46 /

+0.065 (+0.11%)

ALTO Alto Ingredients
$5.73 /

-0.24 (-4.02%)

ABBV AbbVie
$115.62 /

-0.385 (-0.33%)

TAK Takeda Pharmaceutical
$14.46 /

+0.065 (+0.45%)

REGN Regeneron
$615.79 /

-6.7 (-1.08%)

PFE Pfizer
$47.30 /

-1.03 (-2.13%)

MRK Merck
$82.75 /

+0.065 (+0.08%)

CYCN Cyclerion Therapeutics
$2.77 /

-0.09 (-3.15%)

CERE Cerevel Therapeutics
$43.53 /

-0.975 (-2.19%)

BMY Bristol-Myers
$59.46 /

+0.065 (+0.11%)

ALTO Alto Ingredients
$5.73 /

-0.24 (-4.02%)

ABBV AbbVie
$115.62 /

-0.385 (-0.33%)

YMTX Yumanity Therapeutics
$8.43 /

-0.39 (-4.42%)

TAK Takeda Pharmaceutical
$14.46 /

+0.065 (+0.45%)

SHCR Sharecare
$7.22 /

+0.11 (+1.55%)

REGN Regeneron
$615.79 /

-6.7 (-1.08%)

PFE Pfizer
$47.30 /

-1.03 (-2.13%)

MRK Merck
$82.75 /

+0.065 (+0.08%)

BMY Bristol-Myers
$59.46 /

+0.065 (+0.11%)

ABBV AbbVie
$115.62 /

-0.385 (-0.33%)

Conference/Events
Sharecare management to meet virtually with BTIG » 13:22
11/09/21
11/09
13:22
11/09/21
13:22
SHCR

Sharecare

$7.00 /

-0.11 (-1.55%)

Virtual Meeting to be…

Virtual Meeting to be held on November 16 hosted by BTIG.

ShowHide Related Items >><<
SHCR Sharecare
$7.00 /

-0.11 (-1.55%)

SHCR Sharecare
$7.00 /

-0.11 (-1.55%)

10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
08/11/21 BTIG
Sharecare's Q2 results 'excellent,' 'impressive' level of visibility, says BTIG
08/04/21 Canaccord
Sharecare initiated with a Buy at Canaccord
SHCR Sharecare
$7.00 /

-0.11 (-1.55%)

SHCR Sharecare
$7.00 /

-0.11 (-1.55%)

Conference/Events
CNS Summit to hold a summit » 04:55
11/09/21
11/09
04:55
11/09/21
04:55
OTSKY

Otsuka

$19.86 /

-0.25 (-1.24%)

, SYNH

Syneos Health

$101.67 /

+1.78 (+1.78%)

, CERE

Cerevel Therapeutics

$44.41 /

+ (+0.00%)

, TAK

Takeda Pharmaceutical

$14.40 /

+0.14 (+0.98%)

, REGN

Regeneron

$622.38 /

+10.52 (+1.72%)

, PFE

Pfizer

$48.34 /

-0.265 (-0.55%)

, AVNR

Avanir

$16.96 /

+ (+0.00%)

, KRTX

Karuna Therapeutics

$151.57 /

-3.62 (-2.33%)

, ABBV

AbbVie

$116.00 /

-1.17 (-1.00%)

, CYCN

Cyclerion Therapeutics

$2.86 /

-0.01 (-0.35%)

, YMTX

Yumanity Therapeutics

$8.90 /

-0.08 (-0.89%)

, ALTO

Alto Ingredients

$5.96 /

+0.3 (+5.30%)

, APTX

Aptinyx

$2.32 /

-0.045 (-1.90%)

, MRK

Merck

$82.68 /

+1.07 (+1.31%)

, BMY

Bristol-Myers

$59.42 /

-0.03 (-0.05%)

, SHCR

Sharecare

$7.11 /

-0.1 (-1.39%)

12th Annual CNS Summit to…

12th Annual CNS Summit to be held in Boston on November 7-10.

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$8.90 /

-0.08 (-0.89%)

TAK Takeda Pharmaceutical
$14.40 /

+0.14 (+0.98%)

SYNH Syneos Health
$101.67 /

+1.78 (+1.78%)

SHCR Sharecare
$7.11 /

-0.1 (-1.39%)

REGN Regeneron
$622.38 /

+10.52 (+1.72%)

PFE Pfizer
$48.34 /

-0.265 (-0.55%)

OTSKY Otsuka
$19.86 /

-0.25 (-1.24%)

MRK Merck
$82.68 /

+1.07 (+1.31%)

KRTX Karuna Therapeutics
$151.57 /

-3.62 (-2.33%)

CYCN Cyclerion Therapeutics
$2.86 /

-0.01 (-0.35%)

CERE Cerevel Therapeutics
$44.41 /

+ (+0.00%)

BMY Bristol-Myers
$59.42 /

-0.03 (-0.05%)

APTX Aptinyx
$2.32 /

-0.045 (-1.90%)

ALTO Alto Ingredients
$5.96 /

+0.3 (+5.30%)

ABBV AbbVie
$116.00 /

-1.17 (-1.00%)

OTSKY Otsuka
$19.86 /

-0.25 (-1.24%)

07/14/21 Goldman Sachs
Otsuka downgraded to Sell from Neutral at Goldman Sachs
06/17/21 Daiwa
Otsuka upgraded to Outperform from Neutral at Daiwa
03/15/21 Daiwa
Otsuka downgraded to Neutral from Outperform at Daiwa
SYNH Syneos Health
$101.67 /

+1.78 (+1.78%)

11/04/21 Baird
Syneos Health price target raised to $122 from $115 at Baird
11/04/21 Barclays
Syneos Health upgraded to Overweight from Equal Weight at Barclays
08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
CERE Cerevel Therapeutics
$44.41 /

+ (+0.00%)

10/08/21 Jefferies
Cerevel Therapeutics price target raised to $37 from $30 at Jefferies
09/22/21 Stifel
CFO transition impact on Cerevel Therapeutics 'likely minimal,' says Stifel
07/13/21 Stifel
Cerevel Therapeutics price target raised to $33 from $21 at Stifel
06/30/21 Citi
Karuna Therapeutics selloff brings buying opportunity, says Citi
TAK Takeda Pharmaceutical
$14.40 /

+0.14 (+0.98%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
REGN Regeneron
$622.38 /

+10.52 (+1.72%)

11/05/21
Fly Intel: Top five analyst downgrades
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/05/21 H.C. Wainwright
Regeneron price target raised to $844 from $842 at H.C. Wainwright
11/04/21 Piper Sandler
Piper says Regeneron remains 'core holding' after 'another strong beat'
PFE Pfizer
$48.34 /

-0.265 (-0.55%)

11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
AVNR Avanir
$16.96 /

+ (+0.00%)

KRTX Karuna Therapeutics
$151.57 /

-3.62 (-2.33%)

11/08/21 Oppenheimer
Karuna Therapeutics price target raised to $175 from $148 at Oppenheimer
11/05/21 Mizuho
Karuna Therapeutics price target raised to $182 from $150 at Mizuho
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
09/30/21 JPMorgan
Karuna Therapeutics initiated with an Overweight at JPMorgan
ABBV AbbVie
$116.00 /

-1.17 (-1.00%)

11/01/21 Morgan Stanley
AbbVie price target raised to $124 from $116 at Morgan Stanley
10/29/21 Piper Sandler
AbbVie price target raised to $129 from $124 at Piper Sandler
10/19/21 Morgan Stanley
Regenxbio assumed with an Overweight at Morgan Stanley
10/05/21 Piper Sandler
Biohaven Pharmaceutical price target raised to $156 from $140 at Piper Sandler
CYCN Cyclerion Therapeutics
$2.86 /

-0.01 (-0.35%)

10/20/21 Truist
Cyclerion Therapeutics initiated with a Buy at Truist
10/20/21 Truist
Cyclerion Therapeutics initiated with a Buy at Truist
09/24/21 Cantor Fitzgerald
Cyclerion Therapeutics initiated with an Overweight at Cantor Fitzgerald
YMTX Yumanity Therapeutics
$8.90 /

-0.08 (-0.89%)

09/08/21 Piper Sandler
Yumanity should be bought ahead of Parkinson's data, says Piper Sandler
06/04/21 H.C. Wainwright
Yumanity Therapeutics initiated with a Buy at H.C. Wainwright
04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
ALTO Alto Ingredients
$5.96 /

+0.3 (+5.30%)

APTX Aptinyx
$2.32 /

-0.045 (-1.90%)

01/29/21 JPMorgan
Aptinyx downgraded to Underweight from Neutral at JPMorgan
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
11/19/20 H.C. Wainwright
Aptinyx price target raised to $8 from $7 at H.C. Wainwright
11/12/20 Piper Sandler
Aptinyx pipeline catalysts on track, says Piper Sandler
MRK Merck
$82.68 /

+1.07 (+1.31%)

11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
BMY Bristol-Myers
$59.42 /

-0.03 (-0.05%)

11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
11/01/21 Argus
Bristol-Myers cut to Hold at Argus on generic competition threat to Revlimid
11/01/21 Argus
Bristol-Myers downgraded to Hold from Buy at Argus
10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
SHCR Sharecare
$7.11 /

-0.1 (-1.39%)

10/29/21 BTIG
Call with Sharecare customers raises BTIG conviction in long-term outlook
09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
08/11/21 BTIG
Sharecare's Q2 results 'excellent,' 'impressive' level of visibility, says BTIG
08/04/21 Canaccord
Sharecare initiated with a Buy at Canaccord
YMTX Yumanity Therapeutics
$8.90 /

-0.08 (-0.89%)

SYNH Syneos Health
$101.67 /

+1.78 (+1.78%)

SHCR Sharecare
$7.11 /

-0.1 (-1.39%)

REGN Regeneron
$622.38 /

+10.52 (+1.72%)

PFE Pfizer
$48.34 /

-0.265 (-0.55%)

MRK Merck
$82.68 /

+1.07 (+1.31%)

KRTX Karuna Therapeutics
$151.57 /

-3.62 (-2.33%)

CERE Cerevel Therapeutics
$44.41 /

+ (+0.00%)

BMY Bristol-Myers
$59.42 /

-0.03 (-0.05%)

APTX Aptinyx
$2.32 /

-0.045 (-1.90%)

ALTO Alto Ingredients
$5.96 /

+0.3 (+5.30%)

ABBV AbbVie
$116.00 /

-1.17 (-1.00%)

  • 02
    Jul
  • 03
    Jun
  • 04
    May
  • 01
    Mar
  • 02
    Mar
  • 02
    Dec
TAK Takeda Pharmaceutical
$14.40 /

+0.14 (+0.98%)

REGN Regeneron
$622.38 /

+10.52 (+1.72%)

PFE Pfizer
$48.34 /

-0.265 (-0.55%)

OTSKY Otsuka
$19.86 /

-0.25 (-1.24%)

MRK Merck
$82.68 /

+1.07 (+1.31%)

BMY Bristol-Myers
$59.42 /

-0.03 (-0.05%)

ALTO Alto Ingredients
$5.96 /

+0.3 (+5.30%)

ABBV AbbVie
$116.00 /

-1.17 (-1.00%)

TAK Takeda Pharmaceutical
$14.40 /

+0.14 (+0.98%)

REGN Regeneron
$622.38 /

+10.52 (+1.72%)

PFE Pfizer
$48.34 /

-0.265 (-0.55%)

MRK Merck
$82.68 /

+1.07 (+1.31%)

CYCN Cyclerion Therapeutics
$2.86 /

-0.01 (-0.35%)

CERE Cerevel Therapeutics
$44.41 /

+ (+0.00%)

BMY Bristol-Myers
$59.42 /

-0.03 (-0.05%)

ALTO Alto Ingredients
$5.96 /

+0.3 (+5.30%)

ABBV AbbVie
$116.00 /

-1.17 (-1.00%)

YMTX Yumanity Therapeutics
$8.90 /

-0.08 (-0.89%)

TAK Takeda Pharmaceutical
$14.40 /

+0.14 (+0.98%)

SHCR Sharecare
$7.11 /

-0.1 (-1.39%)

REGN Regeneron
$622.38 /

+10.52 (+1.72%)

PFE Pfizer
$48.34 /

-0.265 (-0.55%)

MRK Merck
$82.68 /

+1.07 (+1.31%)

BMY Bristol-Myers
$59.42 /

-0.03 (-0.05%)

ABBV AbbVie
$116.00 /

-1.17 (-1.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.